Navigation Links
Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
Date:7/30/2009

ble levels of virus at weeks 4 and 12 and to achieve SVR; (iii) Anadys' expectation that it will receive 28-day data from the 200 mg dose level by year end and additional data during the first two quarters of 2010; (iv) the antiviral and tolerability profile of ANA598 seen to date, which may not be duplicated in the Phase II study; (v) preclinical properties indicative of likely synergy when used clinically in combination regimens; and (vi) the belief that certain features of the Phase II protocol have the ability to further enhance the competitive position of ANA598. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues or will have favorable results in the planned Phase II trial. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its product candidates, regulatory developments involving its product candidates and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008 and Anadys' Current Report on Form 8-K filed on June 4, 2009. All fo
'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
2. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
3. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
4. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
5. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
6. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
9. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
10. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
11. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Nematicide is a type of chemical ... parasitic roundworms, found in massive quantities virtually everywhere—in ... animals. Nematicides have tended to be broad-spectrum toxicants ... through the soil. A single gram of soil ... more than 10,000 species classified, they are one ...
(Date:9/30/2014)... 30, 2014 Follow us on ... each type of cholesterol carrier or lipoprotein in the ... excessive cholesterol levels in the body, especially along the ... heart attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) ... for cholesterol levels on a regular basis, to assess ...
(Date:9/30/2014)... Fast, semi-automatic creation of ... documents ChemAxon , a leader ... for life science research, launches ChemCurator, an application ... from documents. Markush structures are essential ... and understanding Markush structures is a difficult and ...
(Date:9/30/2014)... Sept. 30, 2014  KemPharm, Inc., a clinical-stage ... development of proprietary new molecular entity (NME) prodrugs, ... Trademark Office (USPTO) issued U.S. Patent No. 8,816,083 ... Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid ... Use Thereof." The patent, which extends ...
Breaking Biology Technology:Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... CLINTON, N.J. and JERUSALEM, July 6 Ikaria Holdings, ... Ikaria has entered into an agreement to obtain a ... treatment for preventing pathological cardiac remodeling following acute myocardial ... phase I/II clinical trial, is administered via the coronary ...
... /PRNewswire-FirstCall/ - avVaa World Health Care Products Inc. (Pink ... of nationally branded therapeutic, natural skin and health care ... an agreement with 3PL Worldwide, Inc., for all Order ... CEO explains that "3PL Worldwide offers true multichannel support ...
... July 6 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: ... the $29.5 million of outstanding 8% Senior Convertible Notes due ... July 1, 2009 is effective as of 8:00 a.m. today. ... with holders of 87% of the Notes, which is above ...
Cached Biology Technology:IKARIA(R) to In-License BioLineRx's BL-1040 2IKARIA(R) to In-License BioLineRx's BL-1040 3avVaa World Health Care Products, Inc. Signs Agreement with 3PL Worldwide, Inc., for Order Management & Fulfillment for avVaa's Product 2Verenium Completes Amendment to 8% Senior Convertible Notes 2Verenium Completes Amendment to 8% Senior Convertible Notes 3Verenium Completes Amendment to 8% Senior Convertible Notes 4
(Date:9/30/2014)... professor and Howard Hughes Medical Institute investigator, and ... recipients in the 2014 round of grants from ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative ... September 30, provides more than $3 million in ... , The BRAIN Initiative, launched last year, is ...
(Date:9/30/2014)... German . FRANKFURT. ... in the world. Because they grow underground, people use trained ... of truffles is not only of interest to gourmets. A ... the Goethe University Frankfurt have discovered that the smell of ... trapped inside truffle fruiting bodies. , White truffles from the ...
(Date:9/30/2014)... hope: A new research report published in October 2014 ... explains how scientists developed a synthetic version of a ... in human and mouse eggs similar to the natural ... fertilization. , "We believe that the results of this ... of human fertilization by providing a precise answer to ...
Breaking Biology News(10 mins):Salk scientists receive $3 million for BRAIN Initiative grant 2On the trail of the truffle flavor 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2
... used topically in many skin creams and cosmetics because ... Now, new research just published in the Journal of ... and how it might actually benefit skin from the ... cocoa may actually help improve the appearance of women's ...
... is the only culprit in the steady increase in the ... challenged by a scientist speaking at the 22nd annual conference ... Prague, Czech Republic, Wednesday 21 June 2006. Professor ... that his research had shown that improved nutrition, both maternal ...
... (LANP) have unveiled the "nanoegg," the latest addition ... of the versatile nanoshell, nanoeggs are asymmetric specks ... harnessed for molecular imaging, medical diagnostics, chemical sensing ... July 18 issue of the Proceedings of the ...
Cached Biology News:New study reveals components of cocoa may enhance the appearance of the skin 2Nutrition a major factor in rise in twin pregnancies 2Nutrition a major factor in rise in twin pregnancies 3Rice scientists unveil 'nanoegg' 2